- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05028621
Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
March 21, 2024 updated by: Case Comprehensive Cancer Center
Exploratory Analysis of the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
The purpose of this study is to use agnostic genomic evaluation using whole exome sequencing (WES) of a variety of rare hematologic diseases grouped under rare blood diseases and its variants to further elucidate the understanding of the chemistry of these disorders and identify potential actionable mutations that can be targeted with therapies in the context of clinical trials.
Study Overview
Status
Suspended
Conditions
Intervention / Treatment
Detailed Description
The study team will examine genetic changes, also known as mutations, in the DNA of participants' blood, or if applicable, bone marrow specimen.
These types of tests are increasingly used by doctors to improve the accuracy of diagnosis and make decisions during care.
This study seeks to understand how many patients will benefit from this testing, and in what ways.
The results of this portion of the study are placed in the individual's medical record and are communicated back to each participant.
Study Type
Interventional
Enrollment (Estimated)
135
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sudipto Mukherjee, MD, PhD
- Phone Number: 1-866-223-8100
- Email: TaussigResearch@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-5065
- Cleveland Clinic, Case Comprehensive Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Must have histopathologic confirmation of the particular rare hematologic disease.
Diseases that will be considered as rare hematologic diseases for this study will include the following
- Langerhans cell histiocytosis (LCH)
- Erdhiem Chester disease (ECD)
- Rosai-Dorfman disease (RDD)
- Miscellaneous histiocytic entities -indeterminate dendritic cell tumor, interdigitating dendritic cell sarcoma, follicular dendritic cell sarcoma, fibroblastic reticular cell tumor
- Unicentric Castleman disease
- Multicentric Castleman disease including TAFRO
- Follicular Dendritic Cell sarcoma (FDCS)
- Newly diagnosed treatment naïve patients as well as patients who received prior therapies (e.g. chemotherapy, targeted therapy, surgery, or radiation) will be included. -Tissue specimens collected within the past 5 yearse will be considered acceptable for study inclusion will include the following
- Collected as part of the evaluation for diagnostic confirmation
- Tissue specimen or extracted DNA (from blood sample) banked in IRB approved tissue repositories and obtained within five years prior to the date of informed consent. -Tissue samples are planned to be collectedfrom previously stored surgical specimens already being stored in pathology lab
- Consent to have germline testing performed in parallel to tumor testingg)Patients willing to receive treatmen
Exclusion Criteria:
- Life expectancy of less than 6months
- Patient unwilling to have germline testing performed on peripheral blood or buccal mucosa
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Genomic analysis
When a participant's disorder was diagnosed, blood or tissue specimen was collected.
A part of the tissue or blood will be sent to an outside company, Tempus, to be tested for specific genetic changes and the results will be sent back to participants' physician.
|
Genetic testing of blood or tissue sample and limited medical information sent to an outside company.
Database will link genome sequence data with human trait information, including cancer and other diseases, to be sent to participant's physician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of genomic analyses yielding genetic aberrations
Time Frame: Up to 12 months from last participant accrued
|
Proportion of genomic analyses yielding actionable genetic aberrations.
"Actionable" is defined as a mutation linked to an approved therapy in the particular disease under study or another disease, a known or suspected contraindication to a given therapy, or a clinical trial linked to the alteration
|
Up to 12 months from last participant accrued
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of genomic analyses yielding actionable genetic aberrations
Time Frame: Up to 12 months from last participant accrued
|
Actionable will be defined as a mutation linked to an approved therapy in the particular disease or another disease, a known or suspected contraindication to a given therapy, or a clinical trial linked to the alteration.
|
Up to 12 months from last participant accrued
|
Proportion of genomic analyses yielding germline genetic aberrations
Time Frame: Up to 12 months from last participant accrued
|
Up to 12 months from last participant accrued
|
|
Referral rates for genetic counseling for germline mutations
Time Frame: Up to 12 months from last participant accrued
|
Number of participants with germline mutations who were referred to genetic counseling through Cancer Genetics for their identified germline mutations
|
Up to 12 months from last participant accrued
|
Completion rates of genetic counseling for germline mutations
Time Frame: Up to 12 months from last participant accrued
|
Number of participants with germline mutations who were referred to, and underwent (completed) genetic counseling through Cancer Genetics.
|
Up to 12 months from last participant accrued
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sudipto Mukherjee, MD, PhD, Cleveland Clinic, Case Comprehensive Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 18, 2021
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
August 25, 2021
First Submitted That Met QC Criteria
August 25, 2021
First Posted (Actual)
August 31, 2021
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE7Z20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Deidentified IPD will be shared to maintain patient confidentiality
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Langerhans-Cell Histiocytosis
-
Tongji HospitalRecruitingLangerhans Cell Histiocytosis | Rosai-Dorfman DiseaseChina
-
Memorial Sloan Kettering Cancer CenterCompletedLangerhans Cell Histiocytosis | Erdheim-Chester Disease | Histiocytic DisordersUnited States
-
Shanghai Henlius BiotechActive, not recruitingLangerhans Cell Histiocytosis | Erdheim-Chester Disease | LCH | ECDChina
-
National Cancer Institute (NCI)RecruitingRecurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell HistiocytosisUnited States
-
Children's Oncology GroupNot yet recruitingRecurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis
-
Children's Hospital Medical Center, CincinnatiRecruitingHistiocytic Disorders | Juvenile Xanthogranuloma (JXG) | Langerhans Cell Histiocytosis (LCH) | Rosai-Dorfman Disease (RDD)United States
-
Peking Union Medical College HospitalRecruiting
-
Histiocyte SocietyCompletedChildhood Langerhans Cell HistiocytosisCanada, United Kingdom, United States, France, Germany, Austria, Ireland, Sweden, Italy, Argentina
-
University of Alabama at BirminghamRecruitingHistiocytosis | Langerhans Cell Histiocytosis | Erdheim-Chester Disease | Rosai Dorfman Disease | Xanthogranuloma | Malignant HistiocytosesUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedAdult Pulmonary Langerhans Cell HistiocytosisFrance
Clinical Trials on Genetic testing
-
Thomas Jefferson UniversityProstate Cancer FoundationActive, not recruitingBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8United States
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecruitingDepression | Suicide, Attempted | Suicide | Major Depressive Disorder | Suicidal Ideas | MDD | Depression and Suicide | Depression in Adolescence | Depression, TeenUnited States
-
ClinLogic LLCMDGlobalRecruitingEarly Detection of CancerUnited States
-
UNICANCERInstitut National de la Santé Et de la Recherche Médicale, France; Gustave... and other collaboratorsRecruitingMutation | Hereditary Breast and Ovarian CancerFrance
-
Data Collection Analysis Business ManagementPAS Research ServicesUnknownEndometrial Cancer | Colon CancerUnited States
-
Southern Medical University, ChinaUnknown
-
Proove Bioscience, Inc.UnknownMental Disorders | Cardiovascular Diseases | Pain | Diabetes Mellitus, Type 2 | Arthritis | Chronic PainUnited States
-
Liggins InstituteRecruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruitingPulmonary Arterial Hypertension | Heart Defects, Congenital | Genetic TestingBelgium
-
Baylor Research InstituteTranslational Genomics Research InstituteUnknown